Affordable Access

deepdyve-link
Publisher Website

A highly secreted sulphamidase engineered to cross the blood-brain barrier corrects brain lesions of mice with mucopolysaccharidoses type IIIA.

Authors
  • Sorrentino, Nicolina Cristina1
  • D'Orsi, Luca
  • Sambri, Irene
  • Nusco, Edoardo
  • Monaco, Ciro
  • Spampanato, Carmine
  • Polishchuk, Elena
  • Saccone, Paola
  • De Leonibus, Elvira
  • Ballabio, Andrea
  • Fraldi, Alessandro
  • 1 Telethon Institute of Genetics and Medicine (TIGEM), Naples, Italy. , (Italy)
Type
Published Article
Journal
EMBO Molecular Medicine
Publisher
EMBO
Publication Date
May 2013
Volume
5
Issue
5
Pages
675–690
Identifiers
DOI: 10.1002/emmm.201202083
PMID: 23568409
Source
Medline
License
Unknown

Abstract

Mucopolysaccharidoses type IIIA (MPS-IIIA) is a neurodegenerative lysosomal storage disorder (LSD) caused by inherited defects of the sulphamidase gene. Here, we used a systemic gene transfer approach to demonstrate the therapeutic efficacy of a chimeric sulphamidase, which was engineered by adding the signal peptide (sp) from the highly secreted iduronate-2-sulphatase (IDS) and the blood-brain barrier (BBB)-binding domain (BD) from the Apolipoprotein B (ApoB-BD). A single intravascular administration of AAV2/8 carrying the modified sulphamidase was performed in adult MPS-IIIA mice in order to target the liver and convert it to a factory organ for sustained systemic release of the modified sulphamidase. We showed that while the IDS sp replacement results in increased enzyme secretion, the addition of the ApoB-BD allows efficient BBB transcytosis and restoration of sulphamidase activity in the brain of treated mice. This, in turn, resulted in an overall improvement of brain pathology and recovery of a normal behavioural phenotype. Our results provide a novel feasible strategy to develop minimally invasive therapies for the treatment of brain pathology in MPS-IIIA and other neurodegenerative LSDs.

Report this publication

Statistics

Seen <100 times